CryoLife, Inc. Product Pipeline Analysis

SUMMARY

CryoLife, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a CryoLife, Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 8
2 Company Snapshot 9
2.1 Key Information 9
2.2 Company Overview 9
2.3 Financial Performance 9
2.4 Industry Outlook -- Cardiovascular Devices 9
3 Business Description 10
3.1 Business Overview 10
3.2 Major Products and Services 10
3.2.1 Overview 10
4 History 12
5 Competitors 13
6 Key Employees 14
7 Key Employee Biographies 15
8 Company Statement 16
9 Locations And Subsidiaries 17
9.1 Head Office 17
10 Recent Developments 18
10.1 Strategy And Business Planning 18
10.1.1 Jan 08, 2008: CryoLife Signs License Agreement With Trophic For Organ Transport Solution 18
10.2 Financial Announcements 18
10.2.1 Jul 31, 2008: CryoLife Declares 2Q 2008 Results 18
10.2.2 Apr 30, 2008: CryoLife Declares Q1 2008 Results 20
10.2.3 Apr 14, 2008: CryoLife To Declare Q1 2008 Results 21
10.2.4 Feb 21, 2008: CryoLife Reports Q4 2007 Results 22
10.2.5 Nov 01, 2007: CryoLife Reports 3Q 2007 Results 23
10.2.6 Oct 11, 2007: CryoLife Declares Preliminary Q3 2007 Results 25
10.2.7 Jul 31, 2007: CryoLife Declares Q2 2007 Results 26
10.2.8 May 01, 2007: CryoLife Declares Q1 2007 Results 28
10.2.9 Mar 13, 2007: CryoLife Declares Preferred Dividend 29
10.2.10 Jan 11, 2007: CryoLife Declares Preliminary Q4 2006 Results 29
10.3 Corporate Communications 30
10.3.1 Aug 04, 2008: CryoLife Announces Senior Management Promotions 30
10.3.2 May 01, 2008: CryoLife Elects New Board Member 30
10.3.3 Apr 08, 2008: CryoLife Appoints Vice President, Medical Relations And Education 30
10.3.4 Oct 30, 2007: CryoLife Announces Management Changes 31
10.3.5 Sep 04, 2007: CryoLife Appoints VP, General Counsel 31
10.4 Product News 32
10.4.1 Jul 01, 2008: Positive Midterm Results Reported For Pulmonary Human Heart Valve 32
10.4.2 Jun 10, 2008: CryoLife, Inc. BioGlue Surgical Adhesive Receives European Approval For Use In Browlift Cosmetic And Reconstructive Plastic Surgery 32
10.4.3 May 13, 2008: CryoLife Inc, Announces First Implant Of Combination Aortic-Mitral Allograft Heart Valve At The Cleveland Clinic 33
10.4.4 Apr 24, 2008: CryoLife Conducts Surgeons Cardiac Allograft Symposium 33
10.4.5 Mar 24, 2008: CryoLife Announces Implant Of First FDA-Cleared SynerGraft Processed Human Pulmonary Heart Valve 34
10.4.6 Feb 07, 2008: CryoLife Receives FDA 510(k) Clearance For SynerGraft Processed Human Pulmonary Heart Valves 34
10.4.7 Sep 17, 2007: CryoLife Signs Distribution Agreement For Inclusion Of BioGlue Surgical Adhesive In Hernia Repair Kit With Proxy Biomedical Surgical Meshes 34
10.4.8 Jun 26, 2007: BioForm Medical Enrolls First Patient In Clinical Trial Of CryoLife's BioGlue Surgical Adhesive For Use In Cosmetic And Plastic Surgery 34
10.4.9 Jun 14, 2007: CryoLife Awarded US Patent For BioFoam 35
10.4.10 Apr 30, 2007: CryoLife's BioDisc Nucleus Pulposus Replacement To Be Featured At Two Medical Conferences In Berlin 35
10.4.11 Jan 10, 2007: CryoLife Announces Agreement With Cleveland Clinic To Develop Innovative Heart Valve For High Risk Patients 35
10.5 Product Approvals 36
10.5.1 Jun 10, 2008: CryoLife, Inc. BioGlue Surgical Adhesive Receives European Approval For Use In Browlift Cosmetic And Reconstructive Plastic Surgery 36
10.5.2 Feb 07, 2008: CryoLife Receives FDA 510(k) Clearance For SynerGraft Processed Human Pulmonary Heart Valves 36
10.6 Clinical Trials 36
10.6.1 Jul 01, 2008: Positive Midterm Results Reported For Pulmonary Human Heart Valve 36
10.6.2 May 13, 2008: CryoLife Inc, Announces First Implant Of Combination Aortic-Mitral Allograft Heart Valve At The Cleveland Clinic 37
10.6.3 Mar 24, 2008: CryoLife Announces Implant Of First FDA-Cleared SynerGraft Processed Human Pulmonary Heart Valve 38
10.6.4 Jun 26, 2007: BioForm Medical Enrolls First Patient In Clinical Trial Of CryoLife's BioGlue Surgical Adhesive For Use In Cosmetic And Plastic Surgery 38
10.7 Other Significant Developments 38
10.7.1 Dec 19, 2006: RTI, CryoLife Enter Into Exchange And Service Agreement 38
11 CryoLife, Inc. Pipeline Products 39
11.1 CryoLife, Inc. Product Pipeline Analysis 39
11.1.1 CryoLife, Inc. Pipeline Products By Equipment Type 39
11.1.2 CryoLife, Inc. Pipeline Products By Development Stage 41
11.1.3 CryoLife, Inc. Pipeline Products By Therapy Area 42
11.1.4 CryoLife, Inc. Pipeline Products By Clinical Trials 42
11.1.5 CryoLife, Inc. Pipeline Products By News Summary 43
11.2 Biodisc 43
11.2.1 Product Description 44
11.2.2 Product Status 44
11.2.3 Clinical Trials 44
11.2.4 Product Milestone 44
11.3 CryoValve SG 45
11.3.1 Product Description 45
11.3.2 Product Status 45
11.3.3 Clinical Trials 46
11.3.4 Product Milestone 46
11.3.5 Product Patent Details 47
11.4 BioFoam 47
11.4.1 Product Description 47
11.4.2 Product Status 48
11.4.3 Product Milestone 48
11.4.4 Product Patent Details 48
12 Appendix 50
12.1 Methodology 50
12.1.1 Coverage 50
12.1.2 Secondary Research 51
12.1.3 Primary Research 51
12.1.4 Expert Panel Validation 52
12.2 Contact Us 52
12.3 About Global Markets Direct 52
12.4 Disclaimer 52

1.1 List of Tables
Table 1: CryoLife, Inc.,Key Facts 9
Table 2: CryoLife, Inc., Key Employees, 14
Table 3: CryoLife, Inc. Pipeline Products by Equipment Type 40
Table 4: CryoLife, Inc. Pipeline Products By Development Stage 41
Table 5: CryoLife, Inc. Pipeline Products By Therapy Area 42
Table 6: CryoLife, Inc. Pipeline Products By Clinical Trials 42
Table 7: CryoLife, Inc. Pipeline Products By News Summaries 43

1.2 List of Figures
Figure 1: CryoLife, Inc. Pipeline Products By Equipment Type 39
Figure 2: CryoLife, Inc. Pipeline Products By Equipment Type 40
Figure 3: CryoLife, Inc. Pipeline Products By Development Stage 41
Figure 4: CryoLife, Inc. Pipeline Products By News Summary 43
Figure 5: Global Markets Direct Methodology 50